|
|
Article: Cambridge Antibody Technology and Human Genome Sciences Announce Second Drug Partnership; - Human Antibody to TRAIL Receptor 1 to be Developed For Cancer Treatment -.
- Article from:
- PR Newswire
- Article date:
- January 8, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MELBOURN, England, and ROCKVILLE, Md. -- Cambridge Antibody Technology and Human Genome Sciences, Inc. today announce that Human Genome Sciences has exercised an option to enter into an exclusive development partnership on a human monoclonal antibody to TRAIL Receptor 1 (TRAIL-R1). The antibody is being evaluated as an anti-cancer drug by Human Genome Sciences. TRAIL Receptor 1, which was discovered by Human Genome Sciences, is preferentially expressed on many solid tumors.
Human Genome Sciences and CAT announced a broad collaboration and product development alliance in March 2000. Under the terms of this agreement, Human Genome Sciences is to develop and sell ...